Navigation Links
Deodorants: Do we really need them?
Date:1/17/2013

New research shows that more than 75 per cent of people with a particular version of a gene don't produce under-arm odour but use deodorant anyway.

The study was based on a sample of 6,495 women who are part of the wider Children of the 90s study at the University of Bristol. The researchers found that about two per cent (117 out of 6,495) of mothers carry a rare version of a particular gene (ABCC11), which means they don't produce any under-arm odour.

While about 5 per cent of people who produce an odour do not use deodorant, more than a fifth (26 out of 117) of those who don't produce an odour do not use deodorant, a statistically highly significant difference. However, 78 per cent of people who do not produce odour, still use deodorant on all or most days.

Speaking about the novel finding, published today in the Journal of Investigative Dermatology, the lead author Professor Ian Day said:

'An important finding of this study relates to those individuals who, according to their genotype, do not produce under-arm odour. One quarter of these individuals must consciously or subconsciously recognise that they do not produce odour and do not use deodorant, whereas most odour producers do use deodorant. However, three quarters of those who do not produce an odour regularly use deodorants; we believe that these people simply follow socio-cultural norms. This contrasts with the situation in North East Asia, where most people do not need to use deodorant and they don't.'

The first author of the paper, Dr Santiago Rodriguez added:

'These findings have some potential for using genetics in the choice of personal hygiene products. A simple gene test might strengthen self-awareness and save some unnecessary purchases and chemical exposures for non-odour producers.'

The authors highlight that people who carry this rare genetic variant are also more likely to have dry (rather than sticky) ear wax and t
'/>"/>

Contact: Dara O'Hare
media@childrenofthe90s.ac.uk
44-011-733-10077
University of Bristol
Source:Eurekalert

Page: 1 2

Related biology news :

1. Thermodynamics really from scratch -- in a new textbook
2. What is really causing the child obesity epidemic?
3. Are we really a nation of animal lovers?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2015)... , July 21, 2015 Passwords ... as seen in the recent U.S. Office of ... solution to the infosec conundrum, but developers and ... stored. To address this dilemma, Biometrics-as-a-Service provider HYPR ... Biometric Tokenization SDK for third party integration. ...
(Date:7/9/2015)... Research and Markets( ... "Biometrics for Banking; Market & Technology Analysis, ... their offering. The adoption for banking ... and the forecast is that by 2020 it ... involved in delivering biometric systems to the banking ...
(Date:7/8/2015)... , July 8, 2015  Trovagene, Inc. (NASDAQ: ... diagnostics, today announced the launch of a study ... Precision Cancer Monitoring℠ (PCM) technology for predicting response ... or a combination of the novel immunotherapy agents ... a PD-1 inhibitor. The 50-patient study will be ...
Breaking Biology News(10 mins):HYPR Corp. Launches Industry First Biometric Tokenization Platform 2HYPR Corp. Launches Industry First Biometric Tokenization Platform 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 4Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4
... Whether it's rice farming or rice research, very few of ... career in an industry that has been a foundation of ... want their children to be rice farmers, and even fewer ... vital importance to the region. , However, an innovative ...
... sound like Saturday cartoons: a strong-boned rat that can't ... the real hero is citrus juice. , Orange and ... long considered an unavoidable aging disease in which bones ... by Texas A&M University's Vegetable and Fruit Improvement Center ...
... more than 25 million people in sub-Saharan Africa, according ... a vaccine against the virus have achieved limited success. ... infection found widely in that region of Africa ?chancroid ... of HIV as much as 10-fold? , That may ...
Cached Biology News:A rice future for Asia 2Orange, grapefruit juice for breakfast builds bones in rats 2Vaccine shown effective against chancroid 2Vaccine shown effective against chancroid 3
(Date:7/30/2015)... Washington , July 30, 2015 ... Market, by Product (Software, Molecular Modeling, PB/PK, PKPD, Trial ... Discovery & Development, Preclinical, Clinical Trial), by End Users ... Biosimulation Market is expected to reach USD 2,107.99 million ... a CAGR of 15.29%. Browse more ...
(Date:7/30/2015)... Kan. , July 30, 2015   ... a pet therapeutics company focused on the licensing, ... companion animals, today announced that its strategic partner ... a dose confirmation study of AT-016, an adipose-derived ... for the treatment of osteoarthritis pain in dogs. ...
(Date:7/30/2015)... across the globe, ISN improves the efficiency and effectiveness of contractor management systems. ISN,s ... reliable contractors in over 80 countries. ... ... Over 60,000 Worldwide Customers In More Than 80 Countries ... Headquartered in Dallas, TX , ISN has additional offices in Calgary ...
(Date:7/30/2015)... -- HIGHLIGHTS:Q2 2015 Results (all changes are ... sales were $697 million compared to $701 million in ... 8%, and changes in foreign currency exchange rates decreased ... , By business unit, organic sales growth was ... SAFC Commercial. , Reported diluted EPS was $0.98 ...
Breaking Biology Technology:Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 5ISN Reaches Over 60,000 Worldwide Customers 2ISN Reaches Over 60,000 Worldwide Customers 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 2Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 4Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 5Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 6Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 7Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 8Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 9Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 10Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 11Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 12Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 13Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 14Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 15Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 16Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 17Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 18Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 19Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 20
... to Launch into High Growth Brazilian Market for ... Aesthera announced today the receipt of ANVISA clearance ... platforms in Brazil. ANVISA (Agencia Nacional de ... and regulatory agency charged with clearing all applications ...
... Sinobiopharma, Inc. (OTC Bulletin Board: SNBP) ("Sinobiopharma" or, the "Company") ... to date this year and guidance on its projected financial ... , ... 4.60 million (US $0.68 million), representing a 127 percent increase ...
... , Connecticut MORRISVILLE, N.C., May 20 Asymchem ... and Drug Products to the pharmaceutical industry, with sites in ... award by Pfizer Inc. as the 2008 Top Intermediates CMO ... center on May 1, 2009. The award was the first ...
Cached Biology Technology:Aesthera Announces ANVISA Clearance to Market Photopneumatic Platforms in Brazil 2Aesthera Announces ANVISA Clearance to Market Photopneumatic Platforms in Brazil 3Sinobiopharma Updates on Progress; Projects Increases in Sales and Revenues In 2009 2Sinobiopharma Updates on Progress; Projects Increases in Sales and Revenues In 2009 3Pfizer Global R&D Presents 2008 Top Intermediates CMO Award to Asymchem 2